Fujifilm India today launched four new diagnostic imaging and healthcare IT solutions at IRIA 2026, highlighting its focus on AI-enabled systems, workflow efficiency, and wider access to advanced imaging across India.
Sun Pharmaceutical will invest Rs 500 crore to set up a drug manufacturing plant in Assam. The project will be rolled out in two phases and is expected to generate direct employment for over 500 people.
.png "Lupin Launches New Epilepsy Drug for Partial-Onset Seizures")
Lupin Pharmaceuticals has officially launched its epilepsy drug, Lacosamide, in the U.S., offering a new treatment option for adults with partial-onset seizures. This generic version of Vimpat is approved by the FDA and strengthens Lupin’s U.S. portf
Cipla Limited has announced their “Win Over Weight” campaign on a national scale to create a new impression of obesity in India.
Sanofi has reported positive phase 3 data for venglustat in type 3 Gaucher disease, showing meaningful neurological improvements and comparable non-neurological outcomes versus enzyme replacement therapy.
Lupin has launched Topiramate Extended-Release Capsules in the U.S. after receiving FDA approval for its ANDA, expanding access to treatments for epilepsy and migraine prevention.
The CDSCO has issued a draft guidance document to help IVD medical device importers file import license applications online through the CDSCO portal and the National Single Window System, aiming to ensure faster and accurate approvals.
Zydus Lifesciences has received tentative FDA approval for dapagliflozin tablets in 5 mg and 10 mg strengths. The drug, used to treat type 2 diabetes, will be manufactured at the company’s SEZ facility in Ahmedabad.
NATCO Pharma gets USFDA tentative approval for its generic Erdafitinib, a treatment for advanced urothelial carcinoma, offering a more affordable option for cancer patients.
.png "AstraZeneca's Datroway Gets FDA Priority Review in TNBC")
AstraZeneca and Daiichi Sankyo’s Datroway has received FDA Priority Review for unresectable or metastatic triple-negative breast cancer patients who are not eligible for immunotherapy, marking a key regulatory milestone.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")